Monoclonal antibodies for treatment of cancer

US8946388B2 · kind B2 · utility

Assignee

• Ganymed Pharmaceuticals GmbH · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Michael Koslowski · Mainz, DE
• Rita Mitnacht-Kraus · Friedberg, DE

Key dates

• Filing date: Sep 16, 2009
• Grant date: Feb 3, 2015
• Expiry date: Apr 14, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/73
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.